116 related articles for article (PubMed ID: 32107349)
1. Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life.
Baldan Ferrari G; Coelho França Quintanilha J; Berlofa Visacri M; Oliveira Vaz C; Cursino MA; Sampaio Amaral L; Brito Bastos ; Pereira TT; de Oliveira Guarnieri JP; de Godoy Torso N; Passos Lima CS; Moriel P
Anticancer Drugs; 2020 Jun; 31(5):523-527. PubMed ID: 32107349
[TBL] [Abstract][Full Text] [Related]
2. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
[TBL] [Abstract][Full Text] [Related]
3. Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients.
Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AK; Tang NL; Chu CM; Hui J; Lee KF; Yu S; Yeo W
Qual Life Res; 2019 Sep; 28(9):2597-2607. PubMed ID: 31037590
[TBL] [Abstract][Full Text] [Related]
4. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
[TBL] [Abstract][Full Text] [Related]
5. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.
Eilard MS; Andersson M; Naredi P; Geronymakis C; Lindnér P; Cahlin C; Bennet W; Rizell M
BMC Cancer; 2019 Jun; 19(1):568. PubMed ID: 31185950
[TBL] [Abstract][Full Text] [Related]
6. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Ye SL; Yang J; Bie P; Zhang S; Chen X; Liu F; Liu L; Zhou J; Dou K; Hao C; Shao G; Xia Q; Chen Y; Yang J; Deng X; Liu Y; Yuan Y; Fu Z; Nakajima K; Lv Z
BMC Cancer; 2018 Mar; 18(1):247. PubMed ID: 29499662
[TBL] [Abstract][Full Text] [Related]
7. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
Goyal L; Zheng H; Abrams TA; Miksad R; Bullock AJ; Allen JN; Yurgelun MB; Clark JW; Kambadakone A; Muzikansky A; Knowles M; Galway A; Afflitto AJ; Dinicola CF; Regan E; Hato T; Mamessier E; Shigeta K; Jain RK; Duda DG; Zhu AX
Clin Cancer Res; 2019 Jan; 25(1):80-89. PubMed ID: 30190369
[TBL] [Abstract][Full Text] [Related]
8. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
[TBL] [Abstract][Full Text] [Related]
9. Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology.
Berk V; Kaplan MA; Tonyali O; Buyukberber S; Balakan O; Ozkan M; Demirci U; Ozturk T; Bilici A; Tastekin D; Ozdemir N; Unal OU; Oflazoglu U; Turkmen E; Erdogan B; Uyeturk U; Oksuzoglu B; Cinkir HY; Yasar N; Gumus M
Asian Pac J Cancer Prev; 2013; 14(12):7367-9. PubMed ID: 24460304
[TBL] [Abstract][Full Text] [Related]
10. Implementation of a Nurse-driven Educational Program Improves Management of Sorafenib's Toxicities in Hepatocellular Carcinoma.
Brunot A; Le Roy F; Le Sourd S; M'Sadek A; Duval M; Crouzet L; Guillygomarc'h A; Boucher E; Laguerre B; Edeline J
Cancer Nurs; 2018; 41(5):418-423. PubMed ID: 28731881
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
12. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
13. The association of liver function and quality of life of patients with liver cancer.
Li L; Mo F; Hui EP; Chan SL; Koh J; Tang NLS; Yu SCH; Yeo W
BMC Gastroenterol; 2019 May; 19(1):66. PubMed ID: 31046687
[TBL] [Abstract][Full Text] [Related]
14. Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
Williet N; Clavel L; Bourmaud A; Verot C; Bouarioua N; Roblin X; Merle P; Phelip JM
Dig Liver Dis; 2017 Sep; 49(9):1043-1049. PubMed ID: 28712860
[TBL] [Abstract][Full Text] [Related]
15. Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.
Fu Y; Wei X; Lin L; Xu W; Liang J
Thorac Cancer; 2018 May; 9(5):542-547. PubMed ID: 29575544
[TBL] [Abstract][Full Text] [Related]
16. Hand-foot skin reaction induced by sorafenib in a hepatocellular carcinoma patient.
Pathania YS
Postgrad Med J; 2020 Aug; 96(1138):495. PubMed ID: 31551240
[No Abstract] [Full Text] [Related]
17. Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment.
Shomura M; Kagawa T; Okabe H; Shiraishi K; Hirose S; Arase Y; Tsuruya K; Takahira S; Mine T
BMC Cancer; 2016 Nov; 16(1):878. PubMed ID: 27835949
[TBL] [Abstract][Full Text] [Related]
18. Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
Shin SY; Lee YJ
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):837-46. PubMed ID: 24075093
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective.
Pearson H; Marshall LV; Carceller F
Pediatr Hematol Oncol; 2020 Aug; 37(5):412-423. PubMed ID: 32183592
[TBL] [Abstract][Full Text] [Related]
20. Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
Kim DY; Kim HJ; Han KH; Han SY; Heo J; Woo HY; Um SH; Kim YH; Kweon YO; Lim HY; Yoon JH; Lee WS; Lee BS; Lee HC; Ryoo BY; Yoon SK
Cancer Res Treat; 2016 Oct; 48(4):1243-1252. PubMed ID: 26910470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
